The predicated demise of racemic new molecular entities is an exaggeration

被引：62

作者：

Agranat, Israel ^{[1
]}

Wainschtein, Silvya R. ^{[1
]}

Zusman, Enav Z. ^{[2
]}

机构：

[1] Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel

[2] Tel Aviv Univ, Dept Life & Med Sci, IL-69978 Tel Aviv, Israel

来源：

NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 12期

关键词：

D O I：

10.1038/nrd3657-c1

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：972 / 973

页数：2

共 11 条

[1] Putting chirality to work: The strategy of chiral switches [J].

Agranat, I ;

Caner, H ;

Caldwell, A .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (10) :753-768

[2] The strategy of enantiomer patents of drugs [J].

Agranat, Israel ;

Wainschtein, Silvya R. .

DRUG DISCOVERY TODAY, 2010, 15 (5-6) :163-170

[3]

[Anonymous], 2012, DRUG STEREOCHEMISTRY

[4] STEREOCHEMISTRY, A BASIS FOR SOPHISTICATED NONSENSE IN PHARMACOKINETICS AND CLINICAL-PHARMACOLOGY [J].

ARIENS, EJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (06) :663-668

[5] Trends in the development of chiral drugs [J].

Caner, H ;

Groner, E ;

Levy, L ;

Agranat, I .

DRUG DISCOVERY TODAY, 2004, 9 (03) :105-110

[6]

Ellery T, 2012, PHARM LIFECYCLE MANA, P160

[7]

Gal J., 2006, CHIRALITY DRUG RES, P3

[8]

Mullard A, 2012, NAT REV DRUG DISCOV, V11, P91, DOI 10.1038/nrd3657

[9]

*US FDA, 1992, FDAS POL STAT DEV NE

[10]

Zusman E. Z., 2012, DRUG INF J, V46, P497

← 1 2 →